Please login to the form below

Not currently logged in
Email:
Password:

PharmaVentures increases its Asia-Pacific presence

Aki von Roy will be based in Auckland, New Zealand

edit-aki2Oxford, UK-headquartered advisory firm PharmaVentures has appointed Aki von Roy as an associate based in Auckland, New Zealand.

He has over 30 years experience in pharma and 16 years in biotech, and has been involved in 18 start up or merger ventures as director or investor.

Von Roy said: “I am delighted to join PharmaVentures, a firm with a proven track record in deal making.”

Formally he was the European president of Bristol-Myers Squibb (BMS), where he was responsible for $2.2bn in sales, more than 7,500 employees and around 40 subsidiaries. In 1997, he retired from BMS to establish RvR Associates, a private investment firm specialising in health and related matters.

Von Roy has also been chairman of private and publicly traded companies such as Genesis R&D, Phylogica, Vital Foods and Phytomedics and currently works as a venture partner at BioPacificVentures and an advisor to Direct Capital.

Fintan Walton, CEO of PharmaVentures, added: “Aki has a unique insight into innovative healthcare in the Asia-Pacific region and he will be a great benefit to both PharmaVentures and its clients.”

26th September 2014

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Red Health

Red Health was formed in 2007 to bring something fresh to the healthcare PR world. Our approach was simple –...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics